Difference between revisions of "Polycythemia vera"
Jump to navigation
Jump to search
m |
|||
| Line 9: | Line 9: | ||
==Ruxolitinib (Jakafi)== | ==Ruxolitinib (Jakafi)== | ||
| − | ===Regimen, Verstovsek et al. | + | ===Regimen, Verstovsek et al. 2014=== |
<span | <span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
Revision as of 23:24, 4 December 2014
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Relapsed, refractory, or intolerant
Ruxolitinib (Jakafi)
Regimen, Verstovsek et al. 2014
Phase II
There were several doses evaluated in this cohort; the median total daily dose was 21.7 mg corresponding to approximately 10 mg PO twice per day.
- Ruxolitinib (Jakafi) 10 mg PO twice per day
Continued until progression or excess toxicity
References
- Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, Gattoni E, Pieri L, Guglielmelli P, Elena C, He S, Contel N, Mookerjee B, Sandor V, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014 Feb 15;120(4):513-20. link to original article contains verified protocol PubMed content property of HemOnc.org